Effects of gliclazide, a new antidiabetic agent, on the platelet release reaction, role of adenylate cyclase
| Autor: | Michel Lagarde, Marc Dechavanne, Jean-Paul Thouverez, Monique Verry |
|---|---|
| Rok vydání: | 1975 |
| Předmět: |
Serotonin
medicine.medical_specialty Adenylate kinase Tritium Cyclase Adenosine Triphosphate Platelet Adhesiveness Thrombin In vivo Internal medicine Cyclic AMP medicine Humans heterocyclic compounds Gliclazide Platelet Carbon Radioisotopes Glucuronidase Aspirin Phosphoric Diester Hydrolases Chemistry Prostaglandins E Dipyridamole Hematology Adenosine In vitro Adenosine Diphosphate Sulfonylurea Compounds Endocrinology Collagen Adenylyl Cyclases medicine.drug |
| Zdroj: | Thrombosis Research. 6:345-355 |
| ISSN: | 0049-3848 |
| DOI: | 10.1016/0049-3848(75)90084-5 |
| Popis: | Gliclazide, a sulphonylurea derivative possessing an “in vivo” hypoglycaemic action, inhibits “in vitro” platelet release induced by thrombin or collagen. It does not alter 14CO2 production from [6-14C] glucose, but opposes its increase by thrombin. It is an activator of adenylate cyclase increasing the level of [3H] cyclic AMP formed within the intact platelets from [3H] adenine or [3H] adenosine. Finally, it inhibits the effects of thrombin and collagen on platelet adenylate cyclase activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|